-+ 0.00%
-+ 0.00%
-+ 0.00%
Johnson & Johnson's Tremfya reduces axial psoriatic arthritis symptoms in Phase 4 trial
Share
Listen to the news
Johnson & Johnson's Tremfya reduces axial psoriatic arthritis symptoms in Phase 4 trial
  • Johnson & Johnson's Tremfya met key endpoints in the Phase 4 STAR trial in adults with psoriatic arthritis involving the spine.
  • Treatment significantly improved axial symptoms versus placebo, with MRI scans confirming reduced sacroiliac joint inflammation.
  • No new safety signals emerged; findings supported Tremfya's established safety profile.
  • Late-breaking results are being presented at the Emirates Society for Rheumatology Annual Meeting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611200800PR_NEWS_USPR_____NY02933) on November 20, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending